alexa Bioequivalence of Alprazolam Sublingual Tablet Formulat
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Bioequivalence of Alprazolam Sublingual Tablet Formulation and Alprazolam Immediate Release Tablet in Healthy Volunteers

Bharat Damle1*, Sanela Tarabar2, Uma Kuruganti3, Penelope Crownover1 and Robert R LaBadie3

1Pfizer Inc, New York, NY, USA

2Pfizer Inc, New Haven, CT, USA

3Pfizer Inc, Groton, CT, USA

*Corresponding Author:
Bharat Damle
Pfizer Inc, 235 East 42nd Street
New York, NY 10017, USA
Tel: +1 212-733-4739
E-mail: [email protected]

Received Date: March 25, 2013; Accepted Date: May 27, 2013; Published Date: June 02, 2013

Citation: Damle B, Tarabar S, Kuruganti U, Crownover P, LaBadie RR (2013) Bioequivalence of Alprazolam Sublingual Tablet Formulation and Alprazolam Immediate Release Tablet in Healthy Volunteers. J Bioequiv Availab 5:149-153. doi: 10.4172/jbb.1000150

Copyright: © 2013 Damle B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Alprazolam immediate release (IR) tablets are currently approved for the management of anxiety disorder or the short-term relief of symptoms of anxiety. A sublingual (SL) formulation of alprazolam, which disintegrates in the mouth without the need for additional fluids, has been developed. The aim of this study was to determine if the alprazolam SL 1 mg tablet was bioequivalent to the alprazolam IR 1 mg tablet in healthy volunteers. In this randomized, open label, two-way crossover, single dose study, subjects were randomized to receive a single alprazolam 1 mg IR tablet during one dosing period and a single 1 mg SL tablet during the other dosing period. The primary pharmacokinetic endpoints were area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration AUC (0-t) and maximum plasma concentration (C max ). Adverse events (AEs) were monitored throughout the study. Bioequivalence was concluded if the 90% confidence intervals (CI) for the ratio of adjusted geometric means for both AUC (0-t) and C max were wholly within 80%-125%. Participants were mostly male (27/28 [96.4%]) and had a mean (standard deviation) age of 35.9 (8.2) years. For the alprazolam 1 mg SL tablet relative to the alprazolam 1 mg IR tablet, the ratio of adjusted geometric means (90% CI) for AUC (0-t) and C max were 95.43% (91.74%, 99.27%) and 88.27% (83.68%, 93.11%), respectively. The incidence of AEs was similar during both treatment periods: 24 participants reported 39 AEs during the alprazolam 1 mg IR treatment period, and 23 participants reported 38 AEs during the alprazolam 1 mg SL treatment period. Bioequivalence was demonstrated between the alprazolam IR and SL 1 mg tablets, suggesting that the clinical performance of the SL tablet will be similar to that of the IR tablet.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version